Report : Asia Pacific Enteral Medical Nutrition Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Indication (Respiratory Disorders, Cancer, Post COVID-19, Gastrointestinal Disorders, Liver Failure, and Others), Nutrition Type (Supplemental and Sole-Source), Form (Powder, Liquid, and Semi-Solid), Product (Standard Protein Diet, High Protein Diet, Fruit Juice Based Oral Nutritional Supplement, and Others), Distribution Channel (Hospital Pharmacies, Retail Stores, and Others), and Age Group [Child (Till 18 Years) and Adults (18+years)]
At 7.6% CAGR, the Asia Pacific Enteral Medical Nutrition Market is speculated to be worth US$ 1,641.69 Million by 2028, says Business Market Insights
According to Business Market Insights’ research, the Asia Pacific enteral medical nutrition market was valued at US$ 1,057.41 million in 2022 and is expected to reach US$ 1,641.69 million by 2028, registering an annual growth rate of 7.6% from 2022 to 2028. Increase in prevalence of cachexia and rise in prevalence of gastrointestinal diseases are the critical factors attributed to the market expansion.
The enteral medical nutrition market players are adopting various strategies, including new product launches, regional expansion, and introduction of various programs for use of enteral nutrition to treat patients, to increase their market share. Enteral medical nutrition is becoming safe and highly effective with continued innovation and technological advances, leading to increased acceptance. Therefore, leading players are significantly investing in R&D to develop advanced products and gain more revenue share.
In June 2020, Otsuka Pharmaceutical Factory Inc. launched ENORAS Liquid in strawberry and coffee flavors for enteral use. The product is a concentrated (1.6 kcal/mL) polymeric enteric nutrition formula based on the latest nutritional information to efficiently provide nutrients and energy in a small amount. It is designed to administer 300 kcal per pouch, which is approximately a third of the recommended daily number of vitamins, and trace elements specified in Dietary Reference Intakes for Japanese.
On the contrary, complications of enteral nutrition hurdle the growth of Asia Pacific enteral medical nutrition market.
- Based on indication, the Asia Pacific enteral medical nutrition market is segmented into respiratory disorders, cancer, post COVID-19, gastrointestinal disorders, liver failure, and others. Respiratory disorders held 41.8% market share in 2022, amassing US$ 441.81 million. It is projected to garner US$ 664.13 million by 2028 to expand at 7.0% CAGR during 2022–2028.
- Based on nutrition type, the Asia Pacific enteral medical nutrition market is segmented into supplemental and sole source. The supplemental segment held 77.4% market share in 2022, amassing US$ 818.17 million. It is projected to garner US$ 1,253.54 million by 2028 to expand at 7.4% CAGR during 2022–2028.
- Based on form, the Asia Pacific enteral medical nutrition market is segmented into powder, liquid, and semi-solid. The semi-solid segment held 54.6% market share in 2022, amassing US$ 577.06 million. It is projected to garner US$ 911.35 million by 2028 to expand at 7.9% CAGR during 2022–2028.
- Based on product, the Asia Pacific enteral medical nutrition market is segmented into standard protein diet, high protein diet, fruit juice based oral nutrition, and others. The standard protein diet segment held 52.5% market share in 2022, amassing US$ 559.59 million. It is projected to garner US$ 849.08 million by 2028 to expand at 7.3% CAGR during 2022–2028.
- Based on distribution channel, the Asia Pacific Enteral Medical Nutrition market is segmented into Hospital Pharmacies, Retail Stores and Other Pharmacies. The Hospital pharmacies segment held 60.8% market share in 2022, amassing US$ 643.20 million. It is projected to garner US$ 988.92 million by 2028 to expand at 7.4% CAGR during 2022–2028.
- Based on Age Group, the Asia Pacific enteral medical nutrition market is segmented into child (till 18 years) and adults (above 18 years). With 90.2% share of the domain, the adults segment dominated the market in 2022. It accrued US$ 953.96 million in 2022 and is estimated to generate US$ 1,469.01 million by 2028 to grow at a CAGR of 7.5% over the forecast period.
Our regional analysis states that China captured 29.5% market share in 2022. It was assessed at US$ 309.29 million in 2022 and is likely to hit US$ 475.27 million by 2028, exhibiting a CAGR of 7.4% during the forecast period.
Key players dominating the Asia Pacific enteral medical nutrition market are Abbott Laboratories; B. Braun Melsungen AG; DSM Nutritional Products AG; Fresenius Kabi AG; Global Health Products, Inc.; Hormel Foods Corporation; Meiji Holdings Co., Ltd.; Nestlé S.A.; Nutricia; and Smartfish AS among others.
Contact Us
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: sam@businessmarketinsights.com